Company profile
Next generation biomedicines and bioprocesses | SynGenSys
We create product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes. Our philosophy is simple: all products and production processes are unique. Therefore core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for a specific purpose.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Aug 2023 to 31 Oct 2024
Cell and gene therapies (CGTs) are emerging treatments for many previously incurable diseases. CGTs are overlapping fields of biomedical research and treatment; however, they can be broadly grouped as follows: * **Cell therapies** treat diseases by modifying certain sets of cells, or using cells to carry a therapy through the body. These cells are cultiva...
